How to Develop Androgen Receptor (AR) PROTACs: Target Selection, Warhead Strategies, and Linker Design

* Please be kindly noted that our services and products are intended for research use by organizations or companies and are not intended for individual use.

Consult with Our Experts

What Is the Androgen Receptor (AR), and Which Forms Are Suitable for PROTAC Development?

The androgen receptor (AR), also known as NR3C4, is a ligand-dependent nuclear receptor and transcription factor. Its activity is regulated by androgen binding, conformational changes, nuclear localization, DNA recognition, and interactions with transcriptional cofactors. In AR-dependent research models, changes in receptor abundance, ligand specificity, and domain composition can substantially alter the biological response to a compound.

Full-length AR contains four major structural regions: the N-terminal domain (NTD), DNA-binding domain (DBD), hinge region, and ligand-binding domain (LBD). The LBD provides the most established starting point for small-molecule PROTAC development because it contains a defined ligand-binding pocket. However, the NTD and DBD offer alternative recognition surfaces when the LBD is difficult to engage or absent from a particular AR variant.

Several AR LBD residues are particularly relevant to degrader design. L702H, W742C/L, H875Y, F877L, and T878A/S can change the shape or chemical environment of the ligand-binding pocket. M896V has also been examined in AR degrader research. Some substitutions alter ligand selectivity, while others can change how the receptor responds to particular ligands.

Table 1. AR Structural Regions and Their Implications for PROTAC Design.

What Have AR PROTAC Studies Revealed About Successful and Failed Designs?

AR degrader research has progressed from early steroid-receptor degradation inducers to structurally optimized heterobifunctional molecules and domain-specific approaches. The central lesson is that AR binding affinity is only one component of degrader activity. A productive molecule must also recruit a compatible E3 ligase, form a productive ternary complex, support target ubiquitination, reach the intracellular target, and produce measurable protein depletion.

Table 2. Developed AR PROTACs and Reported Research Findings.

The research history highlights four transferable lessons:

• Target affinity is a starting point: a ligand must retain its AR-binding mode after linker installation. A high-affinity parent compound does not guarantee a high-affinity conjugate or productive degradation.
• Linker geometry determines whether binding becomes degradation: ARCC-4 and other potent degraders show why the exit vector, linker trajectory, and E3 orientation should be evaluated together.
• Weak E3 binding can still be productive: the ARD-266 design demonstrates that a relatively weak VHL-binding component can support potent degradation when the full ternary system is compatible.
• Domain coverage defines the scope of the degrader: an LBD-directed compound cannot be assumed to bind AR-V7, which lacks the conventional LBD. NTD- and DBD-directed approaches address this structural limitation through different recognition mechanisms.

NTD-Targeting PROTAC Development for AR-FL and AR-V7

Target Site: AR NTD Transactivation Regions Shared by AR-FL and AR-V7

The AR N-terminal domain (NTD) comprises approximately the first 558 amino acid residues of full-length AR and accounts for a substantial portion of the receptor. Unlike the compact, predominantly α-helical LBD, the NTD is intrinsically disordered and does not maintain a single, stable three-dimensional fold. It contains important transcriptional activation regions, including TAU-1 and TAU-5, which contribute to interactions with transcriptional machinery and co-regulatory proteins. These regions form a flexible conformational ensemble rather than a conventional deep binding pocket with fixed dimensions. Local hydrophobic clusters, transient secondary structures, and short-lived interaction surfaces can nevertheless provide recognition opportunities. AR-V7 retains the NTD and DNA-binding domain (DBD) but lacks the conventional LBD, making the shared NTD an important structural region for investigating degradation strategies that do not depend on the androgen-binding pocket.

For NTD-directed PROTAC development, the main structural challenge is identifying a sufficiently defined and accessible recognition surface within a flexible domain. Unlike the LBD, the NTD cannot generally be described by one fixed pocket volume or a single set of pocket-wall residues. Its conformation may change with molecular interactions and the surrounding environment, so a binding surface observed in one structural model may not remain equally accessible across the full conformational ensemble. A suitable target region should support reproducible molecular recognition while allowing the attached linker to extend toward an E3 ligase without disrupting the binding interaction. Because AR-FL and AR-V7 share the NTD but differ in their overall domain composition, structural accessibility and degradation must ultimately be evaluated for both receptor forms rather than inferred from their shared sequence alone.

Warhead Selection: NTD-Binding Antagonists and Noncovalent Ligand Strategies

Unlike the structured AR LBD, the N-terminal domain (NTD) lacks a stable three-dimensional binding pocket. Research on NTD-binding compounds has identified the Tau-5 transactivation region as an important recognition site. EPI-002, an EPI-series antagonist derived from a bisphenol A diglycidyl ether scaffold, provides an early structural template. Its aromatic framework supports interactions with the disordered NTD, while its chlorohydrin group has been proposed to contribute to covalent engagement with the Tau-5 region, including Cys404. BWA-522 was developed using an EPI-002-derived warhead and a CRBN-recruiting component. This demonstrates that a covalent NTD-binding scaffold can be incorporated into a PROTAC while retaining activity against both AR-FL and AR-V7. However, covalent engagement requires careful consideration of residue selectivity and reaction behavior.

NP18 provides a different design direction. Developed by refining NTD-binding structures informed by EPI-002 and the noncovalent antagonist ET516, NP18 achieves reversible NTD recognition without relying on the covalent mechanism of the original EPI scaffold. It degrades AR-FL and AR-V7 with reported DC₅₀ values of approximately 18 and 26 nM, respectively, in 22Rv1 cells. These findings support the development of noncovalent NTD warheads as an alternative to irreversible binding strategies.

• EPI-002-derived warheads: consider aromatic bisphenol-based scaffolds with an NTD-recognition profile. The chlorohydrin-containing structure provides a covalent design precedent, but reactive-group selectivity must be evaluated.
• Noncovalent warheads: explore optimized NTD-binding scaffolds inspired by ET516 and NP18 when reversible engagement and potential degrader recycling are desired.
• Warhead optimization: compare binding affinity, structural modifications, and degradation activity after conjugation. NTD recognition should be confirmed experimentally because its disordered structure makes conventional pocket-based predictions less reliable.

Linker Design: Connecting NTD Binders to E3 Recruiters

BWA-522 provides useful evidence for linker optimization in NTD-directed PROTACs. Researchers selected a solvent-exposed propanediol segment of the EPI-002-derived warhead as the linker attachment site to minimize interference with NTD recognition. Initial VHL-recruiting compounds with flexible linkers of different lengths showed limited degradation. Subsequent designs using a thalidomide-derived CRBN recruiter and semi-rigid or rigid linkers improved AR degradation. The final BWA-522 structure incorporated a conformationally restricted heterocyclic linker, demonstrating the potential advantage of controlling linker geometry rather than relying exclusively on flexible PEG-like chains.

NP18 provides complementary evidence for a more streamlined molecular architecture. Its design uses a thalidomide-derived CRBN ligand connected to the optimized noncovalent NTD-binding component. The resulting molecule achieved potent degradation of both AR-FL and AR-V7. Another useful comparison comes from the ITRI NTD-PROTAC series: compounds sharing the same AR-binding moiety but differing in linker length and E3 recruiter showed different degradation kinetics and intracellular persistence. Notably, ITRI-90 and ITRI-126 exhibited longer intracellular degradation activity than ITRI-125, which contained two additional linker atoms. This suggests that excessive linker extension may affect intracellular stability as well as ternary-complex geometry.

• Attachment position: prioritize solvent-exposed substituents on the NTD warhead, as demonstrated by the propanediol attachment strategy used in BWA-522.
• Linker rigidity: compare flexible, semi-rigid, and heterocyclic rigid linkers. BWA-522 provides a precedent for improving degradation through conformational restriction.
• Linker length: prepare a focused length series rather than assuming longer linkers improve E3 accessibility. Compare degradation kinetics and intracellular persistence.
• Molecular properties: consider linker size, polarity, and chemical stability together with cellular exposure, particularly when designing NTD-directed PROTACs for AR-V7 degradation.

E3 Ligase Selection: CRBN and VHL Recruitment for LBD-Independent Degradation

CRBN and VHL have both been explored in NTD-directed AR degrader research. BWA-522 uses a CRBN-recruiting design, while other NTD-directed approaches have investigated alternative recruiter architectures. The preferred system depends on the NTD warhead, linker orientation, E3 availability, and the biological context in which degradation is measured.

CRBN can be a useful starting point when the selected NTD ligand offers a compatible attachment position and the resulting degrader retains adequate cellular exposure. VHL provides a complementary option for determining whether a different recruited protein surface improves ternary-complex formation or target ubiquitination.

• Compare recruiter geometry: examine whether the E3 ligase can approach the NTD-bound receptor without steric interference.
• Evaluate E3 dependence: confirm that AR depletion depends on the intended recruiter and the ubiquitin-proteasome pathway.
• Monitor molecular properties: compare the complete CRBN- and VHL-recruiting molecules for solubility, stability, and cellular exposure.

Table 3. NTD-Directed AR Degrader Design Summary.

DBD-Targeting Peptide PROTAC Development for AR Variants

Target Site: DBD Dimerization Interface and DNA-Recognition Surface

The AR DNA-binding domain (DBD) is a compact region of approximately 65 amino acid residues, with a molecular mass of roughly 7 kDa. Its structure contains two zinc-finger motifs, each stabilized by a zinc ion coordinated by four cysteine residues. The first zinc finger contains structural elements responsible for recognizing androgen-response elements in DNA, while the second contributes to receptor dimerization and DNA-binding specificity. The DNA-recognition surface is shaped to fit the major groove of DNA, with sequence-specific contacts and a positively charged environment supporting interactions with the negatively charged DNA backbone. In contrast to the enclosed, hydrophobic AR LBD pocket, the DBD primarily presents an exposed DNA-binding surface and a relatively compact protein–protein interaction interface. The dimerization region, often associated with the second zinc finger and its surrounding residues, provides a potential recognition site for approaches designed to interfere with AR–AR association.

For DBD-directed peptide PROTAC development, the dimerization interface is a potential target because it presents a protein–protein recognition surface rather than a conventional small-molecule cavity. A peptide binder must establish sufficient contact with this relatively shallow interface while avoiding interference with the structural integrity of the zinc fingers. Its attachment site should also allow the linker to project away from the DBD surface so that the recruited E3 ligase can approach the target in a productive orientation. The DNA-recognition surface provides another possible region for investigating DBD engagement, but binding there may directly interfere with DNA association without necessarily promoting degradation. Accordingly, structural recognition, disruption of dimerization or DNA binding, and actual protein depletion should be treated as distinct outcomes. Since both AR-FL and AR-V7 retain the DBD, this region offers a potential route to LBD-independent degradation, provided that the selected binder and complete degrader demonstrate effective engagement and degradation of the intended AR species.

Warhead Selection: Peptide Binders Based on AR DBD Interaction Surfaces

The AR DBD presents a relatively flat, extended homodimerization interface rather than a deep binding pocket, making it difficult to target with conventional small molecules. A 2022 study addressed this challenge by designing a 16-amino-acid peptide derived from the AR DBD homodimerization structure (PDB: 1R4I). Using Rosetta-based virtual amino acid screening, the researchers optimized key interface residues to improve binding complementarity and peptide stability. The resulting AR-binding sequence specifically recognized the DBD region spanning amino acids 575–591. A separate 12-amino-acid MDM2-binding peptide was incorporated to recruit the E3 ligase. The resulting peptide PROTAC showed binding affinities of approximately 49.6 nM for AR-V7 and 12.2 nM for MDM2, demonstrating that interface-derived peptides can provide effective recognition of an otherwise difficult-to-target protein surface.

• Interface-derived sequences: use the AR DBD homodimerization structure as a template and optimize key contact residues through computational sequence screening.
• Sequence specificity: prioritize residues responsible for DBD recognition rather than simply selecting peptides that inhibit DNA binding or receptor dimerization.
• Structural stabilization: consider peptide conformational constraints when the linear sequence shows insufficient stability or binding persistence.

Linker Design: Peptide Orientation, Spacer Length, and Conjugation Site

The original AR peptide PROTAC connected the 16-amino-acid AR-binding peptide and 12-amino-acid MDM2-binding peptide through a flexible five-residue GGSGG spacer. This architecture allowed both peptide segments to retain their respective binding functions. However, the linear peptide remained susceptible to degradation and showed limited cellular penetration. To address these limitations, researchers developed an ultrasmall gold nanoparticle delivery system with a particle diameter of approximately 5 nm. Subsequent work introduced a double-stapling strategy to stabilize both the β-sheet-like AR-binding segment and α-helical MDM2-binding segment. The modified peptide showed improved thermal and proteolytic stability, with a reported melting temperature of 59.6°C, without disrupting ternary-complex formation.

• Spacer selection: use flexible glycine/serine-rich linkers such as GGSGG as an initial design, then compare alternative lengths and compositions.
• Peptide orientation: preserve the binding interfaces of both peptide segments when selecting conjugation positions.
• Conformational stabilization: consider hydrocarbon stapling to improve α-helical and β-sheet structural stability.
• Delivery optimization: evaluate nanoparticle-assisted delivery when peptide instability and poor cellular penetration limit degradation activity.

E3 Ligase Selection: MDM2 Recruitment and Alternative E3 Evaluation

MDM2 recruitment has been demonstrated in an AR DBD-targeting peptide-PROTAC design. The peptide recognizes the DBD interface, while the MDM2-recruiting element promotes proximity between the receptor and the E3 ligase. This architecture provides a direct example of how a protein–protein interaction surface can be converted into a degradation strategy.

MDM2 should not be selected solely because it has been used in an earlier peptide degrader. Its availability, recruitment geometry, and independent biological effects should be considered in the intended system. Alternative E3 recruiters may be explored if they can be connected to the peptide without compromising target binding or delivery.

• MDM2-based design: use as a reference architecture when the peptide-binding surface and linker can support productive recruitment.
• Alternative recruiters: assess CRBN, VHL, or other E3 systems only when the proposed conjugate has a plausible binding geometry and suitable chemical compatibility.
• Mechanism controls: confirm that depletion depends on the intended E3 ligase and distinguish degradation from changes caused by the recruiter itself.

Table 4. Design Summary for DBD-Directed Peptide AR PROTACs.

LBD-Directed PROTAC Development for Full-Length AR

Target Site: AR LBD Pocket, Helix 12, and Solvent-Exposed Exit Vectors

The androgen receptor ligand-binding domain (AR LBD) comprises approximately 250 amino acid residues and has a molecular mass of about 28 kDa. Its structure adopts a three-layer antiparallel α-helical sandwich composed of 11 α-helices and four short β-strands forming two antiparallel β-sheets. The central ligand-binding pocket (LBP) is buried within the helical structure and is formed primarily by helices H3, H5, H7, H10, and H11. The pocket is predominantly hydrophobic, providing extensive contact surfaces through hydrophobic interactions and van der Waals forces. Polar residues, including Asn705, Gln711, Arg752, and Thr877, can participate in ligand-specific hydrogen-bonding networks that contribute to molecular recognition. At the C-terminus, H12 is a conformationally flexible structural element. In the canonical agonist-bound conformation, it acts like a lid over the pocket entrance, helping stabilize the bound state while contributing to the activation function 2 (AF-2) surface involved in co-regulator interactions. Therefore, the AR LBD is not a rigid cavity with fixed boundaries; its pocket accessibility and surrounding surface geometry can change with local helix and loop conformations.

Warhead Selection: Antagonist-Derived Ligands, SARMs, and Steroidal Ligands

Published AR PROTAC studies indicate that antagonist-derived ligands are a strong starting point for LBD-directed degrader development because their binding modes and structure–activity relationships are relatively well characterized. ARCC-4 uses an enzalutamide-derived warhead linked to a VHL-recruiting ligand. In a reported cellular study, ARCC-4 achieved a DC₅₀ of approximately 5 nM and a D_max exceeding 95%. ARD-266 provides a second example: it combines a potent AR antagonist with a VHL-recruiting component and achieved DC₅₀ values of 0.2–1 nM, with greater than 95% AR reduction in several AR-positive cellular models. These results support antagonist-derived scaffolds as evidence-based starting points, but they do not establish that every antagonist will produce an effective degrader.

SARMs offer an alternative source of AR-binding scaffolds. The early SARM–Nutlin PROTAC demonstrated that a nonsteroidal AR ligand could be connected to an MDM2 recruiter through a PEG-based linker to induce proteasome-dependent AR degradation. However, the reported reduction in AR abundance was observed after treatment at 10 μM for 7 hours, making this an important proof of concept rather than a benchmark for modern degrader potency. Steroidal ligands can also provide orthosteric AR recognition, but their suitability depends on whether a substituent can tolerate linker attachment and whether the resulting conjugate retains the intended binding and functional profile. The available examples do not establish steroidal warheads as generally superior to nonsteroidal antagonists.

• First choice — antagonist-derived scaffolds: prioritize ligands with established LBD binding modes and identifiable solvent-exposed attachment positions. Enzalutamide-derived ARCC-4 and the antagonist-based ARD-266 series provide useful precedents.
• Alternative — SARM-derived scaffolds: consider when the ligand offers a suitable exit vector or a useful recognition profile. Confirm that conjugation preserves AR binding and produces actual protein depletion rather than relying on the parent ligand's affinity.
• Exploratory option — steroidal scaffolds: evaluate when structural evidence supports a conjugation-tolerant position. Measure both AR engagement and receptor functional activity after derivatization.
• Key selection criterion: compare the parent ligand with its linker-bearing intermediate and complete PROTAC. Retained affinity is necessary, but productive E3 recruitment and degradation must be demonstrated independently.

Linker Design: Attachment Position, Length, Rigidity, and Polarity

ARCC-4 provides direct evidence that linker architecture can substantially change degradation performance even when the AR-binding scaffold and E3 recruiter are retained. In the reported series, compounds 2a–c contained the same enzalutamide-derived warhead and VHL-recruiting component but differed in linker design. Compound 2a was the least potent, compound 2b showed improved activity, and compound 2c, subsequently designated ARCC-4, achieved a DC₅₀ of approximately 5 nM and a D_max exceeding 95% in VCaP cells. Compound 2b also exhibited a hook effect at higher concentrations, illustrating that linker-dependent changes in ternary-complex behavior can influence the concentration–degradation relationship.

The 2024 UBX-390 study provides complementary evidence from a CRBN-based AR degrader series. The researchers prepared 73 compounds using a high-affinity AR LBD-binding warhead and thalidomide- or lenalidomide-based CRBN recruiters. They first varied linear linker lengths and subsequently introduced heterocycles to improve molecular properties. UBX-390, which incorporates a piperazine-based rigid linker and a thalidomide-derived CRBN recruiter, achieved a reported DC₅₀ of approximately 2.41 nM in VCaP cells. This result supports evaluating conformationally restricted linkers rather than assuming that a longer, more flexible chain will perform better. However, the optimal architecture remains scaffold-dependent, and the performance of UBX-390 cannot be attributed to linker rigidity alone.

• Attachment position first: identify a solvent-exposed exit vector on the AR warhead and verify that derivatization preserves essential pocket interactions. If the starting ligand offers multiple modifiable positions, compare them before expanding the linker library.
• Length as a matched series: compare short, intermediate, and longer linkers while holding the warhead and E3 recruiter constant. Use the results to identify a productive distance rather than assuming that additional atoms improve degradation.
• Rigidity as an optimization variable: compare flexible chains with partially rigid architectures, including appropriately positioned cyclic or piperazine-containing elements. Retain rigid designs only when experimental data support improved degradation.
• Polarity and molecular properties: assess hydrophilic segments, heteroatom content, molecular size, solubility, and cellular exposure together. A linker that improves ternary-complex formation may still be unsuitable if the complete molecule has poor intracellular availability.
• Mechanism-based comparison: measure DC₅₀, D_max, concentration-dependent degradation, and time-dependent target recovery. Investigate the hook effect and ternary-complex behavior when degradation decreases at higher concentrations.

The practical recommendation is to build a focused linker matrix rather than optimize linker length in isolation. Start with a small number of attachment positions and linker architectures, identify combinations that preserve AR binding and support productive E3 recruitment, and then refine rigidity, polarity, and stability. This staged approach helps distinguish a poor exit vector from an unsuitable linker length or unfavorable ternary-complex geometry.

E3 Ligase Selection: CRBN, VHL, and Alternative Recruiters

VHL has particularly strong precedent in LBD-directed AR PROTAC research. Both ARCC-4 and ARD-266 use VHL-recruiting components, yet their studies also demonstrate that recruiter affinity alone does not determine degrader potency. ARD-266 was developed using a VHL ligand with relatively weak binding affinity, reported in the micromolar range, but still achieved DC₅₀ values of 0.2–1 nM and greater than 95% AR reduction in the tested cellular models. This finding supports evaluating the complete AR–PROTAC–VHL complex rather than selecting an E3 ligand solely on the basis of its binary affinity.

CRBN is another well-supported option for AR degrader development. In the UBX-390 study, a thalidomide-derived CRBN recruiter was combined with an AR LBD-binding warhead and an optimized piperazine-based linker. The resulting compound achieved a reported DC₅₀ of approximately 2.41 nM in VCaP cells, and experiments using CRBN-deficient cells supported the dependence of degradation on CRBN recruitment. A separate CRBN-mediated AR PROTAC study also found that the attachment position on the TD-106 CRBN-binding scaffold influenced degradation: the 6-position series performed better than corresponding 5- and 7-position series, with the representative compound TD-802 showing a DC₅₀ of 12.5 nM and a D_max of 93% in LNCaP cells. These findings show that recruiter attachment geometry is an important part of E3 selection, not merely a synthetic detail.

Alternative recruiters have also demonstrated activity against AR. The early SARM–Nutlin PROTAC recruited MDM2, while SNIPER(AR)-51 was developed by optimizing the AR ligand, IAP-binding component, and linker. These studies establish MDM2- and IAP-based approaches as additional design options, although their performance should not be assumed to match that of later VHL- or CRBN-based degraders. MDM2 recruitment requires particular attention to the biological consequences of perturbing the MDM2–p53 interaction, while IAP-recruiting compounds may have effects related to IAP biology that are independent of AR depletion.

• VHL — evidence-backed starting point: prioritize when the AR warhead and linker can support productive recruitment geometry. ARCC-4 and ARD-266 provide direct precedents for potent LBD-directed degradation.
• CRBN — complementary comparator: evaluate when the available recruiter chemistry, attachment position, and molecular properties support a favorable design. UBX-390 demonstrates that a CRBN-based architecture can achieve potent AR degradation.
• MDM2 and IAP — alternative strategies: consider when there is a clear structural or experimental rationale. Include controls to distinguish AR-dependent degradation from effects caused by the recruited ligase system itself.
• Optimize the whole ternary system: compare E3 recruitment, linker geometry, target ubiquitination, and cellular exposure. A stronger binary E3 ligand does not necessarily produce a more effective degrader.
• Confirm mechanism: use suitable E3 competition or perturbation experiments, together with ubiquitination and protein-degradation assays, to verify that AR depletion depends on the intended recruiter and degradation pathway.

Table 5. LBD-Directed AR Degrader Design Summary.

PROTAC Design for AR LBD Mutation Hotspots

Target Site: Mutation-Induced Changes Around the LBD Pocket and Helix 11–12

The AR ligand-binding domain (LBD) contains a predominantly hydrophobic cavity of approximately 580–605 ų in selected experimentally determined structures, although its measured volume varies with receptor conformation and the method used for calculation. The surrounding α-helices create a relatively deep, enclosed binding environment, while helix 11 (H11), the connecting H11–H12 loop, and helix 12 (H12) contribute to the pocket's shape and accessibility. Point mutations can change this local architecture by altering side-chain volume, polarity, hydrogen-bonding potential, or the packing of neighboring helices. For example, L702H and W742C/L can modify local interactions within the LBD, whereas H875Y, F877L, and T878A/S can affect the region around H11–H12 and influence the conformation of the ligand-binding pocket. These substitutions do not produce a uniform structural effect: some change local ligand contacts, while others alter pocket geometry or the conformational equilibrium of the receptor. In particular, changes around H11–H12 can produce a more open or rearranged pocket in certain mutant structures, potentially changing the space available to a bound ligand and the accessibility of the surrounding protein surface.

For mutant-directed PROTAC development, these structural changes matter because a warhead optimized for wild-type AR may no longer fit a mutant pocket in the same way. Changes in pocket volume, side-chain orientation, and the position of H12 can affect both ligand recognition and the direction in which a linker can extend toward the surrounding solvent. Structural comparisons should therefore examine the specific mutation and its local conformational effects rather than assuming that all AR mutations enlarge the pocket or weaken ligand binding. The relevant design question is whether the selected warhead can maintain sufficient target engagement while providing a linker exit direction compatible with E3 ligase recruitment in the mutant receptor.

Warhead Selection: Mutation-Selective vs. Broad-Spectrum AR Ligands

AR LBD mutations can alter warhead recognition through changes in side-chain volume, polarity, hydrogen-bonding potential, and local pocket conformation. For example, L702H replaces a hydrophobic leucine with a polar histidine, introducing a new hydrogen-bonding interaction with the Ser779 backbone carbonyl and changing the local environment of the predominantly hydrophobic pocket. F877L reduces side-chain volume and can rearrange the neighboring H11–H12 loop, creating additional space and changing pocket accessibility. In contrast, H875Y introduces a bulkier aromatic side chain that occupies additional cavity space. These structural differences explain why a ligand that binds wild-type AR effectively may show altered affinity or positioning in individual mutant receptors.

ARCC-4 provides an important example of broad-spectrum mutant coverage. Its enzalutamide-derived warhead supported degradation of AR-F876L, T877A, H874Y, L702H, and M896V in the reported study. However, subsequent comparisons with UBX-390 and ARV-110 revealed differences in mutant preference. UBX-390 showed particularly strong degradation of H875Y and T878A, while UBX-390 and ARV-110 performed better than ARCC-4 against W742C, F877L, and M896V. Neither UBX-390 nor ARV-110 effectively degraded L702H under the reported experimental conditions. These findings demonstrate that no single warhead architecture should be assumed to cover all AR mutations.

• Broad-spectrum strategy: start with established antagonist-derived scaffolds such as the enzalutamide-derived ARCC-4 warhead and evaluate binding across a defined mutant panel.
• Mutation-informed optimization: prioritize structural analysis of substitutions that change pocket polarity or volume, particularly L702H, F877L, H875Y, and T878A. Modify peripheral warhead substituents only when structural evidence supports improved mutant recognition.
• Comparative screening: compare different AR-binding scaffolds, including those represented by ARCC-4, UBX-390, and ARV-110, rather than assuming that one successful warhead provides universal mutation coverage.

Linker Design: Preserving Target Engagement Across AR Variants

AR mutations can also change the orientation of a bound warhead and the accessibility of its solvent-exposed substituents, potentially altering the direction in which the linker extends from the LBD. The ARCC-4 development study compared enzalutamide-based PROTACs with different linker architectures and identified compound 2c as the most effective degrader. Similarly, the UBX-390 study evaluated 73 AR degraders, initially varying linear linker lengths and subsequently introducing heterocyclic structures. Its optimized design incorporated a piperazine-based rigid linker and a thalidomide-derived CRBN recruiter. These examples demonstrate that linker geometry and conformational control can substantially influence AR degradation.

• Attachment position: prioritize solvent-exposed warhead substituents and confirm that linker installation preserves binding across wild-type and mutant LBD structures.
• Linker length: compare short, intermediate, and longer linkers using matched warhead and E3 recruiter combinations. Avoid assuming that additional linker atoms improve mutant degradation.
• Conformational flexibility: compare flexible linkers with partially rigid or heterocyclic structures, such as piperazine-containing linkers, to identify geometries compatible with different mutant conformations.
• Mutation-specific validation: measure warhead binding and complete PROTAC degradation separately across the same mutant panel. A retained binding affinity does not guarantee productive ternary-complex formation.

For broad-coverage programs, linker optimization should prioritize architectures that retain degradation across multiple AR variants. For mutation-focused programs, linker attachment position and conformational flexibility should be optimized against the specific mutant structure rather than relying exclusively on wild-type AR models.

E3 Ligase Selection: Matching E3 Recruitment to Mutant AR Degradation

E3 selection should be evaluated independently from warhead affinity. VHL and CRBN provide useful comparison systems for mutant AR programs, but neither recruiter should be assumed to perform equally across every receptor conformation. A mutation may preserve binary AR binding while changing the geometry of the complete ternary complex.

When a mutant retains warhead binding but shows weak degradation, changing the E3 recruiter can be more informative than repeatedly increasing warhead potency. The objective is to test whether a different recruited surface and linker trajectory improve ubiquitination of the mutant protein.

• Establish a reference: characterize a wild-type AR degrader before interpreting mutant-specific differences.
• Compare recruiter systems: evaluate VHL and CRBN where feasible, keeping other design elements consistent.
• Measure E3 dependence: use suitable recruiter competition, E3 perturbation, or mechanism controls to verify that degradation follows the intended pathway.
• Consider the experimental context: E3 abundance and activity can differ between systems and may influence the observed degradation profile.

Table 6. AR Mutation-Hotspot Degrader Design Summary.

BOC Sciences Support for AR PROTAC Development

BOC Sciences supports AR programs at each of those decision points, from receptor-form assessment through warhead and linker design, synthesis, and mechanistic evaluation.

Table 7. Representative AR Degrader Reagents and Building Blocks.

AR Target Selection and Mutation/Variant Feasibility Assessment

• Define which receptor species are present in the model: full-length, missense-mutant, splice-variant, or overexpressed
• Map available binding surfaces by receptor form and identify which sites are retained in LBD-truncated variants
• Assess pocket mutations for their likely effect on warhead class selection using published structural and structure-activity information
• Deliver target degradability assessment for TPD development that weighs receptor turnover, accessible ubiquitination surfaces, and ligase availability

AR Warhead Selection and Ligand Design

• Triage antagonist-derived, SARM, steroidal, NTD, and DBD-directed ligand options against the defined receptor form
• Identify solvent-exposed exit vectors and design multiple attachment-site analogues rather than a single conjugate
• Design broad-coverage chemotypes when mutant or variant coverage is required
• Supply AR ligands, degrader reference compounds, and recruiter building blocks, supported by PROTAC design based on bioinformatics

Linker and E3 Ligase System Design with Custom PROTAC Synthesis

• Build focused matrices varying attachment site, length, composition, and rigidity using PEG, alkyl, aromatic, heterocyclic, and click-compatible linkers from the linker library
• Pair warheads with CRBN, VHL, IAP, and MDM2 recruiters and compare degradation outcomes early rather than late
• Prepare parent warhead, non-degrading recruiter control, and matched-linker controls for mechanism interpretation
• Deliver purification and analytical characterization of custom AR degrader candidates, with support through PROTAC scale-up production when quantities increase

Mechanistic and Developability Evaluation

• Measure binary binding and cellular target engagement after warhead derivatization
• Confirm receptor polyubiquitination with protein ubiquitination services and quantify degradation depth by degradation ability assay
• Measure permeability with the PROTAC cellular permeability assay, since AR degraders are large and frequently lipophilic
• Extend promising candidates into exposure studies using PROTAC in vivo PK evaluation in animal models

Explore featured products that can expand your research options and accelerate your next discovery.

Access end-to-end service solutions that help bring efficiency, flexibility, and expertise to your research pipeline.

News

• Protein Degradation with New Chemical Modalities: Successful Strategies in Drug Discovery and Chemical Biology
• Degrader Building Blocks for Targeted Protein Degradation
• Recent Progress of PROTACs Targeting Non-enzymatic Functional Proteins
• Discovery of Molecular Glue Degraders

Technical Information

• Proteolysis-Targeting Chimeras (PROTAC)
• Targeted Protein Degradation: The Next Frontier in Drug Discovery
• Overview of 12 Targeted Protein Degradation Technologies
• Peptide and Small Molecule Based PROTACs Technology